Cipla launches Yurpeak to strengthen diabetes and obesity care
Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as “Cipla”) has announced the launch of Yurpeak® (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM)—two of the country’s most pressing health challenges. Cipla has the rights to distribute and promote Yurpeak®—the second brand of Lilly’s tirzepatide in India,…
